Article information
Resumen
Padecer un trastorno funcional digestivo (TFD) no es fácil. Muchos pacientes preferirían tener una enfermedad orgánica y un informe médico en el que se describiesen los resultados de alguna prueba concluyendo que se observa una lesión. Por tanto, es fundamental adquirir nuevos conocimientos sobre las causas y tratamientos de estas dolencias. El objetivo de este capítulo es resumir de la manera más fácil y útil posible los trabajos más relevantes sobre TFD y trastornos motores digestivos presentados en el Congreso de la Asociación Americana de Gastroenterología (DDW 2010).
Lo más destacable se refiere al estudio de los mecanismos patogénicos y búsqueda de nuevas terapias en trastornos muy prevalentes, como la dispepsia funcional, el síndrome del intestino irritable o el estreñimiento, pero también ha habido estudios interesantes en incontinencia, gastroparesia, síndrome de vómitos cíclicos o acalasia.
Cada vez está más claro que los TFD son de origen multifactorial y que tanto los factores genéticos como ambientales, psicológicos, microinflamatorios y neuroinmunoendocrinos forman parte de su complejo puzle. Cada año somos partícipes de los avances que se producen en el ámbito mundial con la esperanza de que repercutan en el bienestar de nuestros pacientes.
Palabras clave:
Trastornos funcionales digestivos
Dispepsia funcional
Síndrome del intestino irritable
Estreñimiento funcional
Incontinencia
Motilidad digestiva
Acalasia
Abstract
Functional gastrointestinal (GI) disorders are difficult to live with. Many patients would prefer to have an organic disease and a medical report stating the results of a test providing evidence of a lesion. Therefore, further knowledge of the causes and treatment of these disorders is essential. The present article aims to summarize as simply and usefully as possible the most important studies on functional and motor GI disorders presented at the Congress of the American Gastroenterological Association (Digestive Disease Week 2010).
The most notable presentations concerned the pathogenic mechanisms and search for new therapies in highly prevalent disorders such as functional dyspepsia, irritable bowel syndrome and constipation but interesting studies were also presented on incontinence, gastroparesis, cyclic vomiting syndrome and achalasia.
It is increasingly clear that functional GI disorders are caused by multiple factors and, therefore, that genetic, environment, psychological, microinflammatory and neuroimmune-endocrine factors form part of this complex puzzle. Each year, advances are made in distinct parts of the world, which will hopefully improve patient well-being.
Keywords:
Functional gastrointestinal disorders
Functional dyspepsia
Irritable bowel syndrome
Functional constipation
Incontinence
Gastrointestinal motility
Achalasia
Full text is only aviable in PDF
Bibliografía
[1.]
S.J. Coen, A.D. Farmer, M. Kano, S. Fukudo, Q. Aziz.
Phenotyping visceral pain in humans using psychophysiological and brain imaging techniques.
DDW, (2010), pp. 475g
[2.]
L. Liu, Q. Li, M.M. Shenoy, T. Colak, K.R. Mehta, P.J. Pasricha.
Depression and sensitivity to stress can be induced by transient gastric irritation in the neonatal period: behavioral and molecular correlates.
DDW, (2010), pp. M1278
[3.]
S.M. O’Mahony, H.M. Savignac, T. O’Brien, P. Scully, E.M. Quigley, J. Marchesi, et al.
Early-Life Dysbiosis Leads to Visceral Hypersensitivity in Adulthood.
DDW, (2010), pp. 25
[4.]
E. Aizawa, Y. Sato, T. Kochiyama, J. Morishita, M. Kano, M. Kanazawa, et al.
Altered brain activity during rule changes in irritable bowel syndrome.
DDW, (2010), pp. M1292
[5.]
N.A. Koloski, M. Jones, J.S. Kalantar, M.D. Weltman, J. Zaguirre, N. Talley.
Psychological distress predicts developing new functional gastrointestinal disorders (FGIDs) among healthy community subjects: a 12-year prospective, population-based cohort study.
DDW, (2010), pp. 730
[6.]
N.A. Koloski, M. Jones, J.S. Kalantar, M.D. Weltman, J. Zaguirre, N. Talley.
Psychological distress is a major risk factor for the continuation of functional gastrointestinal disorders (FGIDs) 12 years later in the general population.
DDW, (2010), pp. 1001
[7.]
M.M. Walker, A. Warwick, C.Y. Ung, N. Talley, L. Kjelstrom, H. Nyhlin, et al.
The Popcol Study: epidemiology by endoscopy in a swedish adult random population. Intraepithelial lymphocyte and eosinophil counts in the normal colon and irritable bowel syndrome.
DDW, (2010), pp. T1819
[8.]
A. Watson, L.A. Houghton, A.B. Lenton, A. Power, A.K. Jones.
Comparison of placebo analgesia between functional GI and organic non-GI disorders.
DDW, (2010), pp. W1385
[9.]
F. Toyoshima, T. Oshima, S. Nakajima, T. Yamasaki, T. Tomita, Y. Kim, et al.
Association of the 5HT-2a receptor gene -1438g/a polymorphism in patients with functional dyspepsia.
DDW, (2010), pp. M1313
[10.]
T. Tanimura, K. Adachi, K. Furuta, S. Ohara, T. Morita, K. Koshino, et al.
Relationship between upper-GI symptoms and duodenal acidity during acid infusion into stomach.
DDW, (2010), pp. T1088
[11.]
A. Patel, V. Kushnir, G.S. Sayuk, C.P. Gyawali.
The Impact of gastric emptying studies in the management of functional dyspepsia.
DDW, (2010), pp. W1399
[12.]
S. De Kort, J.W. Kruimel, I. Arts, J.P. Sels, N. Schaper, A. Masclee.
Prevalence of gastrointestinal symptoms in diabetics is related to psychological factors.
DDW, (2010), pp. M1331
[13.]
K. Tominaga, H. Suzuki, E. Umegaki, H. Kusunoki, N. Tomotsugu, K. Higuchi, et al.
Rabeprazole improves the symptoms of functional dyspepsia. A double-blind randomized placebo-controlled multi-center trial in Japan: the CAESAR Study.
DDW, (2010), pp. 383
[14.]
H. Kusunoki, K. Haruma, H. Imamura, N. Manabe, H. Sugioka, Y. Saito, et al.
Therapeutic efficacy of Z-338 (acotiamide hydrochloride) in patients with functional dyspepsia is based on enhanced post-prandial gastric accommodation and emptying: confirmed by real-time ultrasonography.
DDW, (2010), pp. 1068
[15.]
L.E. Mazzoleni, G.B. Sander, C.F. Francesconi.
Dyspeptic symptoms after eradication of Helicobacterpylori in patients with functional dyspepsia. Heroes-12 Trial (Helicobacter Eradication Relief of Dyspetic Symptoms).
DDW, (2010), pp. W1416
[16.]
Y. Yamazaki, I. Yoshida, H. Matsuda, T. Ohno, S. Matsunaga, M. Ohtani, et al.
A ten-year study on the long-term effect of Helicobacterpylori eradication therapy on dyspepsia symptoms in Japan.
DDW, (2010), pp. T1096
[17.]
Y.A. Saito, J.J. Larson, E.J. Atkinson, E. Ryu, A.E. Almazar Elder, R.M. Lee, et al.
A candidate gene association study of functional “psychiatric” polymorphisms in irritable bowel syndrome (IBS).
DDW, (2010), pp. 667
[18.]
Y.A. Saito, J.J. Larson, E.J. Atkinson, E. Ryu, A.E. Almazar Elder, N. Talley, et al.
A serotonin-pathway candidate gene association study of irritable bowel syndrome (IBS).
DDW, (2010), pp. 671
[19.]
S.E. Jun, K.C. Cain, M. Jarrett, M. Heitkemper.
Tryptophan hydroxylase gene variants and IBS symptoms.
DDW, (2010), pp. 953
[20.]
S. Singh, G. Meyer, H. Gong.
Identification of novel metabolites in serum of patients with irritable bowel syndrome.
DDW, (2010), pp. S1315
[21.]
D. Piacentino, R. Cantarini, M. Alfonsi, E. Alzari, D. Badiali, N. Pallotta, et al.
The validity of ROME III irritable bowel syndrome subtypes as classified by a gastrointestinal symptom questionnaire and by a daily diary card is enhanced by somatisation.
DDW, (2010), pp. S1310
[22.]
B.M. Spiegel, R.E. Bolus, L.A. Harris, S.L. Lucak, E. Esrailian, W.D. Chey, et al.
Patient-reported symptom relief from current therapy is a robust marker of illness severity in IBS.
DDW, (2010), pp. 865
[23.]
J.M. Lackner, C. Ma, C. Baum, A.M. Brasel, A. Smith, T. Sapaleva, et al.
What do IBS symptom severity scales measure? GI symptoms, emotions, cognitions-or something else?.
DDW, (2010), pp. 863
[24.]
J.F. Tack.
Otilonium bromide improves symptoms and delays time to post-treatment relapse in irritable bowel syndrome patients.
DDW, (2010), pp. S1297
[25.]
P.M. Hellström, M. Degerblad, E. Naslund.
GLP-1 action on preand postprandial antro-duodeno-jejunal motility in healthy subjects and patients with irritable bowel syndrome.
DDW, (2010), pp. S1312
[26.]
B.M. Spiegel, R.E. Bolus, J. Talley, L. Chang.
Patient willingness to use ROSE-010: a subcutaneous (SC) GLP-1 analogue for IBS pain episodes.
DDW, (2010), pp. S1316
[27.]
M. Pimentel, A. Lembo, W.D. Chey, Y. Ringel, S. Zakko, S.M. Mareya, et al.
Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (target 1 and target 2).
DDW, (2010), pp. 475i
[28.]
J.Y. Chou, R. Tabrizi, M. Pimentel, T. Sokol.
Presumed IBS subjects with short remission after antibiotic therapy often have secondary causes for their symptoms.
DDW, (2010), pp. S1326
[29.]
E. Scarpellini, V. Giorgio, S. Filoni, V. Ojetti, M. Gabrielli, G. Gigante, et al.
Efficacy of rifaximin for SIBO treatment in IBS children.
DDW, (2010), pp. W1907
[30.]
P.D. Sawant, J. Venkatraman, P.R. Ducrotté.
Evaluation of Lactobacillusplantarum 299v efficacy in IBS: results of a randomized placebo-controlled trial in 200 patients.
DDW, (2010), pp. T2030
[31.]
B.K. Cha, C.H. Choi, E.K. Baek, H.W. Lee, J.H. Do, S.K. Chang.
The effect of probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: randomized, double-blind, placebo-controlled trial.
DDW, (2010), pp. S1314
[32.]
P. Brown, D.S. Riff, J. Jackson, K. Frazier, E. Clark, Q.M. Yang, et al.
LX1031, a novel locally-acting inhibitor of serotonin (5-HT) synthesis significantly improves symptoms in patients with IBS.
DDW, (2010), pp. 907
[33.]
J.F. Tack, M.S. Harris, S. Proksch, J.D. Bornstein, P.B. Miner.
AST-120 (spherical carbon adsorbent) improves pain and bloating in a randomized, double-blind, placebo-controlled trial in patients with non-constipating irritable bowel syndrome (IBS).
DDW, (2010), pp. S1298
[34.]
S.A. Mueller-Lissner, M.A. Kamm, A. Wald, U. Hinkel, U. Koehler, E. Richter, et al.
Multi-center, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate (SPS) in patients with chronic constipation.
DDW, (2010), pp. S1320
[35.]
M.A. Kamm, S.A. Mueller-Lissner, A. Wald, U. Hinkel, E. Richter, R. Swallow, et al.
Stimulant laxatives are effective in chronic constipation: multi-center, 4-week, double-blind, randomized, placebo-controlled trial of bisacodyl.
DDW, (2010), pp. S1321
[36.]
S.A. Mueller-Lissner, M.A. Kamm, A. Wald, J. Bubeck, E. Richter, U. Hinkel.
Patients can self-manage their stimulant laxative dose to achieve effective relief of chronic constipation, as demonstrated in two randomized trials.
DDW, (2010), pp. S1328
[37.]
J.F. Tack, R. Kerstens, G. Beyens, P. Robinson, L. Vandeplassche.
Long-term tolerability and safety of oral prucalopride in patients with chronic constipation-comparison of double-blind and long-term open label data.
DDW, (2010), pp. T1015
[38.]
V. Stanghellini, R. Kerstens, L. Vandeplassche.
Long-term efficacy of oral prucalopride in patients with chronic constipation.
DDW, (2010), pp. S1300
[39.]
S. Hayashi, N. Kurata, A. Yamaguchi, K. Takeuchi.
Lubiprostone, an inhibitor of CLC-2, prevents NSAID-induced small intestinal damage in rats through EP4 receptor-dependent mechanism.
DDW, (2010), pp. W1347
[40.]
S. Fukudo, M. Hongo, H. Kaneko, R. Ueno.
Efficacy of lubiprostone in patients with constipation with or without irritable bowel syndrome in Japan: randomized, placebo-controlled and dosefinding study.
DDW, (2010), pp. S1309
[41.]
J. Cuppoletti, D.H. Malinowska, K. Tewari, J. Chakrabarti, R. Ueno.
Methadone, but not morphine, inhibits stimulated chloride currents in CLC-2 transfected cells in culture.
DDW, (2010), pp. 1010
[42.]
B.L. Cryer, S. Katz, R. Vallejo, C.B. Scott, T.R. Joswick, G. Dolecek, et al.
A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain.
DDW, (2010), pp. 906
[43.]
A. Lembo, H. Schneier, B.J. Lavins, S.J. Shiff, J.E. MacDougall, X.D. Jia, et al.
Efficacy and safety of once daily linaclotide administered orally for 12-weeks in patients with chronic constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.
DDW, (2010), pp. 286
[44.]
R.T. Carson, S. Tourkodimitris, J.E. MacDougall, B.E. Lewis, S.J. Shiff, B.J. Lavins, et al.
Effect of linaclotide on quality of life in adults with chronic constipation: results from two randomized, double-blind, placebo-controlled phase 3 trials.
DDW, (2010), pp. 847d
[45.]
J.M. Johnston, H. Schneier, B.J. Lavins, S.J. Shiff, J.E. MacDougall, C.B. Kurtz, et al.
Results from the randomized withdrawal period of a phase 3 clinical trial of linaclotide in chronic constipation.
DDW, (2010), pp. T1817
[46.]
M. Simren, H. Abrahamsson, A. Bajor, H. Graffner.
The IBAT inhibitor A3309 – a promising treatment option for patients with chronic idiopathic constipation (Cic).
DDW, (2010), pp. S1299
[47.]
C.B. Patel, M. Ragupathi, N. Bhoot, T.B. Pickron, E.M. Haas.
Patient satisfaction and outcomes following stapled transanal rectal resection (STARR) for obstructed defecation syndrome.
DDW, (2010), pp. 862
[48.]
S. Kindt, N. Rommel, J.F. Tack.
Diagnostic (DIS) agreement between conventional manometry criteria and the Chicago classification of esophageal motility disorders in tertiary care patients.
DDW, (2010), pp. 64
[49.]
G.E. Boeckxstaens, V. Annese, S.B. Des Varannes, S. Chaussade, M. Costantini, I. Elizalde, et al.
The European Achalasia Trial: a randomized multi-centre trial comparing endoscopic pneumodilation and laparoscopic myotomy as primary treatment of idiopathic achalasia.
DDW, (2010), pp. 285
[50.]
V. Oruganti, P. Sachdeva, R.S. Fisher, H.P. Parkman.
Cyclic vomiting syndrome in adults: relationship to cannabis use, migraine headaches, and intervening symptoms.
DDW, (2010), pp. M1324
[51.]
D. Cherian, P. Sachdeva, R.S. Fisher, H.P. Parkman.
Abdominal pain: an under appreciated symptom in gastroparesis.
DDW, (2010), pp. M1321
[52.]
H.P. Parkman, M. Jacobs, A.K. Mishra, J. Kramarczyk, J. Gaughan, E. Krynetskiy.
Pharmacogenetic analysis of patients treated with domperidone for gastroparesis: associations with clinical response and side effects.
DDW, (2010), pp. 1064
[53.]
H.P. Parkman, M. Jacobs, A.K. Mishra, J. Kramarczyk, J. Gaughan, E. Krynetskiy, et al.
DNA microarray SNP analysis of domperidone efficacy in patients with gastroparesis.
DDW, (2010), pp. W1392
[54.]
J.M. Larson, B. Moshiree, W. Drane, A. Tavakkoli, P.P. Toskes.
Azithromycin is equivalent to erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis.
DDW, (2010), pp. W1418
[55.]
R. McCallum, N. Ejskjaer, P. Hellstrom, R.A. Malik, T.V. Nowak, J.C. Pezzullo, et al.
TZP-101, a potent ghrelin receptor agonist, is effective in diabetic patients with delayed gastric emptying and severe nausea/vomiting: phase 2 subset study data.
DDW, (2010), pp. 475h
[56.]
R. McCallum, W.J. Snape, J.M. Wo, F.J. Brody, H.P. Parkman, T.V. Nowak, et al.
Enterra® gastric electrical stimulation for idiopathic gastroparesis: results from a multicenter randomized study.
DDW, (2010), pp. 1065
[57.]
I. Sarosiek, K. Roeser, J. Forster, R.A. Hejazi, J. Sarosiek, R. McCallum.
New surgery for gastroparesis-enterra plus pyloroplasty: its efficacy in different etiologies of gastroparesis.
DDW, (2010), pp. W1405
[58.]
D. Kunkel, M.D. Makhani, K. Chong, C. Chang, M. Pimentel.
Methane on breath testing is associated with constipation: a systematic review and meta-analysis.
DDW, (2010), pp. T2085
[59.]
G. Chiarioni, A. Nardo, I. Vantini, A. Romito, W.E. Whitehead.
Randomized controlled trial comparing biofeedback, electrogalvanic stimulation, and massage for the treatment of levator ani syndrome.
DDW, (2010), pp. 168
[60.]
A.E. Bharucha, L.J. Melton, C. Schleck, A.R. Zinsmeister.
A population-based case-control study of fecal incontinence (FI).
DDW, (2010), pp. 731
[61.]
V. Vitton, K. Baumstarck-Barrau, S. Brardjanian, M. Bouvier, J.C. Grimaud.
Impact of high-level sport practice on the prevalence of anal incontinence in a young healthy female population.
DDW, (2010), pp. 903
Copyright © 2011. Elsevier España S.L.. Todos los derechos reservados
